Table 1 Summary of study design.

Number of patients, doses of hyperpolarized [1-13C]pyruvate given, and types of MR examinations performed in each component of the study are provided.

Study componentDose
(ml/kg)
n patientsType of MR
acquisition
Phase 1: Dose escalation0.1431D dynamic MRSI
33D MRSI
0.2831D dynamic MRSI
33D MRSI
0.4331D dynamic MRSI
32D MRSI
Phase 2: Refining MR methods0.4352D dynamic MRSI
32D MRSI
53D MRSI